X4 Pharmaceuticals (XFOR) Misses Q3 EPS by 69c

X4 Pharmaceuticals (NASDAQ: XFOR) reported Q3 EPS of ($0.69). Revenue for the quarter came in at $1.76 million.

For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.

You May Also Be Interested In

• FDA accepts Teva's drug application for Tourette syndrome therapy in children
• Cosmos Health posts 29% revenue gain in Q2 but widens net loss
• Estee Lauder shares jump as fiscal 2027 profit forecast tops estimates